Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Cyclo Therapeutics, Inc.Financial_Report.xls
EX-10.1 - BUSINESS LOAN AGREEMENT - Cyclo Therapeutics, Inc.f10q0913ex10i_ctdholdings.htm
EX-31.1 - CERTIFICATION - Cyclo Therapeutics, Inc.f10q0913ex31i_ctdholdings.htm
EX-10.10 - COMMERCIAL GUARANTY - NANOSONIC PRODUCTS, INC. - Cyclo Therapeutics, Inc.f10q0913ex10x_ctdholdings.htm
EX-10.5 - COMMERCIAL GUARANTY - NANOSONIC PRODUCTS, INC. - Cyclo Therapeutics, Inc.f10q0913ex10v_ctdholdings.htm
EX-10.15 - COMMERCIAL GUARANTY - NANOSONIC PRODUCTS, INC. - Cyclo Therapeutics, Inc.f10q0913ex10xv_ctdholdings.htm
EX-10.6 - COMMERCIAL GUARANTY - CYCLODEXTRIN TECHNOLOGIES DEVELOPMENT, INC. - Cyclo Therapeutics, Inc.f10q0913ex10vi_ctdholdings.htm
EX-10.4 - ASSIGNMENT OF LEASES, RENTS AND PROFITS - Cyclo Therapeutics, Inc.f10q0913ex10iv_ctdholdings.htm
EX-10.2 - PROMISSORY NOTE - 578,988 - Cyclo Therapeutics, Inc.f10q0913ex10ii_ctdholdings.htm
EX-10.9 - COMMERCIAL SECURITY AGREEMENT - Cyclo Therapeutics, Inc.f10q0913ex10ix_ctdholdings.htm
EX-10.11 - COMMERCIAL GUARANTY - CYCLODEXTRIN TECHNOLOGIES DEVELOPMENT, INC. - Cyclo Therapeutics, Inc.f10q0913ex10xi_ctdholdings.htm
EX-10.12 - COMMERCIAL GUARANTY - SPHINGO BIOTECH, INC. - Cyclo Therapeutics, Inc.f10q0913ex10xii_ctdholdings.htm
EX-10.13 - PROMISSORY NOTE - 100,000 - Cyclo Therapeutics, Inc.f10q0913ex10xiii_ctdholdings.htm
EX-10.17 - COMMERCIAL GUARANTY - SPHINGO BIOTECH, INC. - Cyclo Therapeutics, Inc.f10q0913ex10xvii_ctdholdings.htm
EX-10.8 - PROMISSORY NOTE - 295,890 - Cyclo Therapeutics, Inc.f10q0913ex10viii_ctdholdings.htm
10-Q - QUARTERLY REPORT - Cyclo Therapeutics, Inc.f10q0913_ctdholdings.htm
EX-10.7 - COMMERCIAL GUARANTY - SPHINGO BIOTECH, INC. - Cyclo Therapeutics, Inc.f10q0913ex10vii_ctdholdings.htm
EX-10.14 - COMMERCIAL SECURITY AGREEMENT - Cyclo Therapeutics, Inc.f10q0913ex10xiv_ctdholdings.htm
EX-10.16 - COMMERCIAL GUARANTY - CYCLODEXTRIN TECHNOLOGIES DEVELOPMENT, INC. - Cyclo Therapeutics, Inc.f10q0913ex10xvi_ctdholdings.htm
EX-10.3 - MORTGAGE - Cyclo Therapeutics, Inc.f10q0913ex10iii_ctdholdings.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this Form 10-Q of CTD Holdings, Inc. (the “Company”) for the fiscal quarter ended September 30, 2013, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, C.E. Rick Strattan, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 
(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: November 13, 2013     
By:
/s/ C.E. Rick Strattan 
   
C.E. Rick Strattan
Chief Executive Officer
(principal executive, financial and accounting officer)